Premium
In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review
Author(s) -
Yamashita Akiko,
Hidaka Nobuhiro,
Yamamoto Ryo,
Nakayama Soichiro,
Sasahara Jun,
Ishii Keisuke,
Mitsuda Nobuaki
Publication year - 2015
Publication title -
journal of clinical ultrasound
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.272
H-Index - 61
eISSN - 1097-0096
pISSN - 0091-2751
DOI - 10.1002/jcu.22214
Subject(s) - betamethasone , medicine , in utero , fetus , gestation , congenital cystic adenomatoid malformation , gestational age , obstetrics , hydrops fetalis , prenatal diagnosis , ultrasound , survival rate , pregnancy , gynecology , surgery , radiology , biology , genetics
Fetal congenital cystic adenomatoid malformation (CCAM) can progress to nonimmune hydrops, and the mortality rate of CCAM with hydrops is reported to be nearly 100%. We describe three microcystic CCAM cases in which the fetal condition improved after maternal betamethasone therapy. The median gestational age at steroid administration was 23 5/7 weeks' gestation. The CCAM decreased in size in all cases. Our series showed a 100% hydrops resolution rate (2/2) and a 100% survival rate (3/3). Our experience suggests the efficacy of betamethasone treatment on fetuses with microcystic CCAM who have fluid collection or are at risk of developing hydrops. © 2014 Wiley Periodicals, Inc. J Clin Ultrasound 43 :451–457, 2015